Capital Expenditure, Depreciation and Amortization
Percentage of R&D Expenses in Revenue
Research and Development Expenses
Number of Employees
(Million ¥)
FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | ||
---|---|---|---|---|---|---|
Capital Expenditure | 11,346 | 10,773 | 11,138 | 14,408 | 18,313 | |
Depreciation and Amortization | 10,152 | 11,278 | 12,259 | 13,221 | 13,774 | |
Research and Development Expenses | 10,235 | 10,338 | 10,363 | 10,731 | 11,582 | |
Percentage of R&D Expenses in Revenue | 4.8% | 5.0% | 5.0% | 4.1% | 4.1% | |
Number of Employees at End Period | 5,898 | 5,969 | 7,937 | 7,916 | 8,044 | |
Non-consolidated | 1,632 | 1,624 | 1,612 | 1,538 | 1,594 | |
Subsidiaries and Affiliates | 4,266 | 4,345 | 6,325 | 6,378 | 6,450 |
Remark
(i) | Calculation method of financial indexes
|
---|
Topics More
- 2024/02/29 IR Notice of Revision of Dividend Forecast
- 2024/02/05 IR Summary of Consolidated Business Results for the Nine Months Ended December 31, 2023
- 2024/01/31 IR Notice Concerning Share Split and Partial Amendment to the Articles of Incorporation
- 2023/11/06 IR Summary of Consolidated Business Results for the Six Months Ended September 30, 2023
- 2023/10/31 IR Notice Concerning Dividends of Surplus (Interim Dividend)